Over the past month Vaxart, Inc. (VXRT) had 6 sessions that stood out against its own volatility, and they ran mostly lower. The biggest was a 9.1% drop, a move that was largely stock-specific.2026-09-04 — $0.4950 (+0.51%)Vaxart rose 0.51% to $0.50, though on light volume (0.4x the 20-day average). Shares opened with a 1.52% gap...
Key Points - Multiple law firms encouraging Capricor Therapeutics investors with losses over $100k to take...
Key Points - Rosen Law Firm announces a class action lawsuit on behalf of Flotek Industries,...
The Children's Place, Inc. (PLCE) confirmed earnings release on September 04, 2026, After the market for...
KNOT Offshore Partners LP (KNOP) confirmed earnings release on September 04, 2026, After the market for...
from D.A. Davidson issued a price target of $22.00 for MAMA on 2026-09-04 13:04:14.The adjusted price target was set to $22.00.At the time of the announcement, MAMA was trading at...
Ted Jackson from Northland Securities issued a price target of $16.00 for MTRX on 2026-09-04 12:52:50.The adjusted price target was set to $16.00.At the time of the announcement, MTRX was...
from Lake Street issued a price target of $22.00 for MAMA on 2026-09-04 12:49:05.The adjusted price target was set to $22.00.At the time of the announcement, MAMA was trading at...
from Lake Street issued a price target of $16.00 for AOUT on 2026-09-04 12:38:15.The adjusted price target was set to $16.00.At the time of the announcement, AOUT was trading at...
Matt Koranda from Roth Capital issued a price target of $17.00 for AOUT on 2026-09-04 11:01:34.The adjusted price target was set to $17.00.At the time of the announcement, AOUT was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
